Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has announced the closure of its trading window for dealing in company securities, effective from July 1, 2025, until 48 hours after the declaration of financial results for the quarter ending June 30, 2025. This is a standard compliance measure under SEBI's Insider Trading Regulations, 2015, and applies to directors, designated persons, their immediate relatives, and all connected persons covered under the company's code of conduct. The date of the board meeting to declare the Q1 FY26 financial results will be communicated separately. The notice was signed by Ch. Venkat Ramesh, Company Secretary & Compliance Officer, on June 26, 2025.
This is a routine regulatory compliance announcement and does not have a direct impact on shareholders or stock price. However, the upcoming board meeting for Q1 FY26 results is worth watching, as it could provide meaningful business updates and trigger a stock reaction once results are declared.